July 3, 2019 — The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next generation of real-world research on behalf of cardiovascular disease and diabetes patients around the world. As part of this partnership, Veradigm — which simplifies healthcare with data-driven health insights and technologies to help manage costs and improve health outcomes — will operate two registries:
-
The Pinnacle Registry, which focuses on coronary artery disease, hypertension, heart failure, atrial fibrillation and diabetes in the outpatient setting; and
-
The Diabetes Collaborative Registry, the first global, cross-specialty clinical registry designed to track and improve the quality of diabetes and metabolic care across the primary care and specialty care continuum from the American College of Cardiology.
The Pinnacle and Diabetes Collaborative Registries will extend Veradigm’s electronic health record (EHR)-enabled ambulatory research network to create a large-scale chronic disease network with more than 250,000 clinicians and 150 million patients including Veradigm partner data sets in the United States. In addition to integrating Veradigm’s technology, data and analytic capabilities with the registries, the partnership will leverage Veradigm’s large specialist and primary care provider network. This will utilize its EHR platforms to bring ACC’s clinical guidelines, decision pathways, education, and wealth of provider and patient engagement tools to the point of care.
“It is essential that clinicians have access to the most comprehensive clinical information that technology allows for to provide their patients with the best possible care,” said Richard J. Kovacs, M.D., FACC, president of the American College of Cardiology. “Through this partnership, we are committing to innovative ways to further the field of cardiology and fulfilling our mission to transform cardiovascular care and improve heart health by delivering a wider breadth of clinical tools and research opportunities to registry participants.”
For more information: www.veradigmhealth.com
March 04, 2026 
